Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Leriglitazone

            Therapeutic Area: Genetic Disease Product Name: MIN-102

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: European Investment Bank

            Deal Size: $29.0 million Upfront Cash: Undisclosed

            Deal Type: Funding October 30, 2020

            Details:

            The EU bank will grant long-term financing to Minoryx to drive the company’s research and development activities in orphan genetic diseases which includes Pivotal Phase 2/3 ADVANCE study, Phase 2 NEXUS study and Phase 2 FRAMES study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Leriglitazone

            Therapeutic Area: Genetic Disease Product Name: MIN-102

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sperogenix Therapeutics

            Deal Size: $78.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement September 23, 2020

            Details:

            Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.